Stock listing

TSX:NVS Novartis AG Stock

Canadian listing (TSX) of Novartis AG · home listing SIX Swiss:NOVN

Follow Novartis AG into a list and get an email when it puts out news.

Share price · TSX:NVS

$31.20 CAD +1.49 (+5.0%)

Close on Oct 27, 2026

Day range
$30.68 – $31.20 CADOct 27, 2026
Volume
1,865 sharesOct 27, 2026
Market cap
$255.8B CADAt the close on Oct 27, 2026 · price × 8.20B shares outstanding
Novartis AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:NOVN · Home128.78 CHF+1.30 (+1.0%)5,167,108129.00131.42127.62127.48Close on Oct 27, 2026
NYSE:NVS$156.86 USD+5.74 (+3.8%)3,734,192$154.15$156.99$154.13$151.12Close on Oct 27, 2026
OTC:NVSEF$150.12 USD+0.31 (+0.2%)—$150.12$150.12$150.12$149.81Close on Oct 27, 2026
Frankfurt:NOTA€139.00 EUR+3.00 (+2.2%)—€135.00€142.00€135.00€136.00Close on Oct 27, 2026
B3:N1VS3484.08 BRL+8.48 (+11.2%)1,14083.1284.0882.8875.60Close on Oct 27, 2026
TSX:NVS$31.20 CAD+1.49 (+5.0%)1,865$31.00$31.20$30.68$29.71Close on Oct 27, 2026
LSE:0K9E$156.40 USD+6.97 (+4.7%)328$149.61$157.13$149.61$149.43Close on Oct 27, 2026
Stuttgart:NOT€138.70 EUR+3.70 (+2.7%)—€138.02€141.24€136.00€135.00Close on Oct 27, 2026
Munich:NOT€140.20 EUR+1.04 (+0.7%)36€138.56€140.20€138.56€139.16Close on Oct 27, 2026
Dusseldorf:NOT€137.86 EUR+3.78 (+2.8%)—€137.86€137.86€137.86€134.08Close on Oct 27, 2026
Stuttgart:NOTA€140.00 EUR——€138.00€140.00€137.00—Close on Oct 27, 2026
Ticker
TSX:NVS
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
TSX
Currency
CAD

What changed lately

Calls

Replays

  • Novartis (SIX Swiss: NOVN) Q3 2026 Earnings Call

    Tue, Oct 27, 2026 · 7:00 AM ET

    Watch Transcript

  • Novartis (SIX Swiss: NOVN) Q2 2026 Earnings Call

    Tue, Jul 21, 2026 · 8:00 AM ET

    Watch Transcript

  • Novartis (SIX Swiss: NOVN) Q1 2026 Earnings Call

    Tue, Apr 28, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance

Oct 27, 2026

Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile

Oct 23, 2026

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)

Oct 21, 2026

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Oct 7, 2026

CAS ประกาศความร่วมมือกับ Novartis เพื่อขับเคลื่อนระบบข้อมูลด้านปฏิกิริยาเคมีที่พร้อมรองรับ AI

Sep 29, 2026

Issued by another party

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Sep 18, 2026

Sironax Announces Option Exercise and Asset Purchase

Sep 16, 2026

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Sep 8, 2026

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Sep 4, 2026

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Sep 1, 2026

All Novartis AG news

Decks

Novartis AG on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
90 in the last 12 months · 117 in all · newest Oct 27, 2026 · oldest 2025
Calls
26 calls with a replay · 26 with a transcript · latest Oct 27, 2026
Decks
40 decks · latest Oct 27, 2026

Where Novartis AG is listed

ListingExchangeCountryCurrency
SIX Swiss:NOVN · Home listingSIX SwissSwitzerlandCHF
NYSE:NVSNYSEUnited StatesUSD
Xetra:NOTXetraGermanyEUR
gettex:NOTgettexGermanyEUR
OTC:NVSEFOTCUnited StatesUSD
Tradegate:NOTTradegateGermanyEUR
Milan:1NOVNMilanItalyEUR
BCBA:NVSBCBAArgentinaARS
LSIN:0QLRLSINUnited KingdomCHF
gettex:NOTAgettexGermanyEUR
LS Exchange:904278LS ExchangeGermanyEUR
SIX Swiss:NOVNEESIX SwissSwitzerlandCHF
BX Swiss:NOTBX SwissSwitzerlandCHF
Frankfurt:NOTFrankfurtGermanyEUR
Frankfurt:NOTAFrankfurtGermanyEUR
VIE:NOVNViennaAustriaEUR
B3:N1VS34B3BrazilBRL
Tradegate:NOTATradegateGermanyEUR
TSX:NVS · This pageTSXCanadaCAD
Lang & Schwarz:904278Lang & SchwarzGermanyEUR
Aquis:NOVNZAquisUnited KingdomCHF
Cboe Canada:NOVNCboe CanadaCanadaCAD
LSE:0K9ELSEUnited KingdomUSD
Cboe Canada:NVSCboe CanadaCanadaCAD
Stuttgart:NOTStuttgartGermanyEUR
BCBA:NVSDBCBAArgentinaUSD
Munich:NOTMunichGermanyEUR
LS Exchange:907122LS ExchangeGermanyEUR
BMV:NVSNBMVMexicoMXN
BCBA:NVSCBCBAArgentinaUSD
BMV:NOVNNBMVMexicoMXN
Hamburg:NOTHamburgGermanyEUR
BOATS:NVSBOATSUnited StatesUSD
Dusseldorf:NOTDusseldorfGermanyEUR
BCBA:NVSBBCBAArgentinaARS
Stuttgart:NOTAStuttgartGermanyEUR
Dusseldorf:NOTADusseldorfGermanyEUR
Hanover:NOTHanoverGermanyEUR
Frankfurt:NOT1FrankfurtGermanyEUR
Turquoise:NOVNZTurquoiseUnited KingdomCHF
BIVA:NOVNNBIVAMexicoMXN
Lang & Schwarz:907122Lang & SchwarzGermanyEUR
Munich:NOTAMunichGermanyEUR
Frankfurt:NOT0FrankfurtGermanyEUR
Hamburg:NOTAHamburgGermanyEUR
BCBA:NVS.CIBCBAArgentinaARS

Log in to ask 6ix AI your own questions about Novartis AG.